GSK PLC Transfer of Treasury Shares

RNS Number : 0288I

GSK PLC

22 March 2024

 

GSK plc

(the 'Company')

 

Transfer of Treasury Shares

 

 

On 21 March 2024, the Company transferred 27,800,000 ordinary shares of 31 1/4 pence each ("Ordinary Shares") that were held by the Company in treasury ("Treasury Shares") to JPMorgan Chase Bank, N.A., the depositary of the Company's American depositary receipts ("ADR") programme, to procure the issuance and transfer of 13,900,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the "Trust"), to be used to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Trust of $41.93 per ADR, representing $20.965 per Ordinary Share, was funded by a contribution to the Trust from GlaxoSmithKline LLC.

 

Following the transfer and as at 22 March 2024, the Company's issued share capital consisted of 4,314,051,101 Ordinary Shares, of which 169,171,155 were held as Treasury Shares.

 

Therefore, the total number of voting rights in the Company is 4,144,879,946. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Notifications may be sent to [e-mail].

 

 

V A Whyte

Company Secretary

 

22 March 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

POSFLFLRVAIFFIS